Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

M6620 und Irinotecanhydrochlorid bei der Behandlung von Patienten mit soliden Tumoren, die metastasiert sind oder nicht chirurgisch entfernt werden können

11. November 2026 aktualisiert von: National Cancer Institute (NCI)

Klinische Phase-I-Studie mit M6620 (VX-970, Berzosertib) in Kombination mit dem Topoisomerase-I-Inhibitor Irinotecan bei Patienten mit fortgeschrittenen soliden Tumoren

This phase I trial studies the side effects and best dose of M6620 and irinotecan hydrochloride in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). M6620 and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Intervention / Behandlung

Detaillierte Beschreibung

PRIMARY OBJECTIVE:

I. To determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of M6620 (VX-970, berzosertib) in combination with irinotecan hydrochloride (irinotecan) in patients with advanced solid tumors.

SECONDARY OBJECTIVES:

I. To estimate the safety and tolerability of M6620 (VX-970, berzosertib) in combination with irinotecan.

II. To document anti-tumor activity. III. To determine the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of M6620 (VX-970, berzosertib) and irinotecan.

EXPLORATORY OBJECTIVE:

I. To identify molecular subpopulations of patients with increased sensitivity to the irinotecan and M6620 (VX-970, berzosertib) combination.

OUTLINE: This is a dose-escalation study.

Patients receive irinotecan hydrochloride intravenously (IV) over 90 minutes and M6620 IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy and collection of blood samples throughout the study and undergo CT at screening, throughout the study, and during follow up.

After completion of study treatment, patients are followed up for 30 days, then at 3 and 6 months.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

66

Phase

  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • California
      • Los Angeles, California, Vereinigte Staaten, 90033
        • USC / Norris Comprehensive Cancer Center
      • Los Angeles, California, Vereinigte Staaten, 90033
        • Los Angeles General Medical Center
      • Palo Alto, California, Vereinigte Staaten, 94304
        • Stanford Cancer Institute Palo Alto
      • Pasadena, California, Vereinigte Staaten, 91105
        • Keck Medical Center of USC Pasadena
      • Sacramento, California, Vereinigte Staaten, 95817
        • University of California Davis Comprehensive Cancer Center
      • San Francisco, California, Vereinigte Staaten, 94115
        • UCSF Medical Center-Mount Zion
    • Connecticut
      • New Haven, Connecticut, Vereinigte Staaten, 06520
        • Yale University
      • New Haven, Connecticut, Vereinigte Staaten, 06510
        • Smilow Cancer Center/Yale-New Haven Hospital
    • Florida
      • Gainesville, Florida, Vereinigte Staaten, 32610
        • UF Health Cancer Institute - Gainesville
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02215
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, Vereinigte Staaten, 02215
        • Dana-Farber Cancer Institute
      • Boston, Massachusetts, Vereinigte Staaten, 02115
        • Brigham and Women's Hospital
      • Boston, Massachusetts, Vereinigte Staaten, 02114
        • Massachusetts General Hospital Cancer Center
    • Michigan
      • Detroit, Michigan, Vereinigte Staaten, 48201
        • Wayne State University/Karmanos Cancer Institute
    • Missouri
      • City of Saint Peters, Missouri, Vereinigte Staaten, 63376
        • Siteman Cancer Center at Saint Peters Hospital
      • Creve Coeur, Missouri, Vereinigte Staaten, 63141
        • Siteman Cancer Center at West County Hospital
      • St Louis, Missouri, Vereinigte Staaten, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Vereinigte Staaten, 63129
        • Siteman Cancer Center-South County
      • St Louis, Missouri, Vereinigte Staaten, 63136
        • Siteman Cancer Center at Christian Hospital
    • North Carolina
      • Chapel Hill, North Carolina, Vereinigte Staaten, 27599
        • UNC Lineberger Comprehensive Cancer Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
        • UPMC Hillman Cancer Center
    • Tennessee
      • Nashville, Tennessee, Vereinigte Staaten, 37232
        • Vanderbilt University/Ingram Cancer Center
      • Nashville, Tennessee, Vereinigte Staaten, 37204
        • Vanderbilt Breast Center at One Hundred Oaks

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Patients must have histologically confirmed metastatic or unresectable malignancy that is refractory to standard therapy or for which no standard therapy exists and where irinotecan is deemed a reasonable treatment option

  • FOR PATIENTS ENROLLED IN THE EXPANSION COHORT: Patients must have known deficiencies in the deoxyribonucleic acid (DNA)-Damage Response (DDR), e.g. mutations in ATM, PALB2, BRCA1/2 or other deficiencies after discussion with the Study Chair (prioritized), or patients can be enrolled with the following tumor types regardless of known DDR deficiency: pancreatic cancer, colorectal cancer, and small cell lung cancer

  • Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) with conventional techniques or as >= 10 mm (>= 1 cm) with spiral CT scan, magnetic resonance imaging (MRI), or calipers by clinical exam

  • No limit on prior lines of therapy for metastatic disease; prior adjuvant or neoadjuvant chemotherapy does not count as a prior line of therapy as long as completion of the adjuvant or neoadjuvant therapy was more than 1 year prior to patient enrollment

  • Age >= 18 years. Because no dosing or adverse event data are currently available on the use of M6620 (VX-970, berzosertib) in combination with irinotecan in patients < 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials

  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Karnofsky >= 70%)

  • Life expectancy of greater than 12 weeks

  • Leukocytes >= 3,000/mcL

  • Absolute neutrophil count >= 1,500/mcL

  • Platelets >= 100,000/mcL

  • Total bilirubin within normal institutional limits

  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal (ULN); if liver involvement, =< 5 x ULN

  • Creatinine clearance >= 60 mL/min/1.73 m^2

  • Patients must have archived tumor tissue from prior tumor biopsy or surgical resections available for submission that is sufficient to complete molecular profiling

  • FOR PATIENTS ENROLLED IN THE EXPANSION COHORT: Willingness to undergo mandatory biopsies (day -13, approximately 18 to 22 hours post end of irinotecan infusion and day 2, approximately 18 to 22 hours post end of irinotecan infusion [= 17 to 21 hours post end of M6620 (VX-970, berzosertib)]); patients enrolled to this cohort should have tumors deemed easily accessible for biopsies with low likelihood of complication

  • The effects of M6620 (VX-970, berzosertib) on the developing human fetus are unknown; for this reason and because DNA-damage response (DDR) inhibitors may have teratogenic potential, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of M6620 (VX-970, berzosertib) administration

    • For this reason and because DNA-damage response (DDR) inhibitors may have teratogenic potential, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 6 months after study completion
  • Ability to understand and willingness to sign a written informed consent document

Exclusion Criteria:

  • Patients who have had chemotherapy or other systemic therapy or radiotherapy or patients who have not recovered from adverse events due to prior administered agents as follows:

    • Chemotherapy < 4 weeks prior to entering the study
    • Radiotherapy < 4 weeks prior to entering the study
    • Nitrosoureas/mitomycin C < 6 weeks prior to entering the study
    • Targeted therapy < 2 weeks (or 5 half-lives, whichever is longer) prior to entering the study
    • Those who have not recovered from clinically significant adverse events due to prior agents administered to grade =< 1 or baseline, with exception of alopecia and peripheral neuropathy, unless approved by the protocol chair
    • Immunotherapy < 4 weeks prior to entering the study
  • Patients who are receiving any other investigational agents

  • Patients with unstable brain metastases should be excluded; however, patients with known brain metastases may participate in this clinical trial if they are clinically stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are on a stable or decreasing dose of steroids for at least 14 days prior to trial treatment

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970, berzosertib) or irinotecan

  • M6620 (VX-970, berzosertib) is primarily metabolized by CYP3A4; irinotecan and its active metabolite, SN-38, are metabolized by CYP3A4 and UGT1A1, respectively; therefore, concomitant administration with strong inhibitors or inducers of CYP3A4 should be avoided; valproic acid is known to inhibit the process of glucuronidation and may potentially enhance the toxicity of irinotecan; medications that enhance glucuronidation (i.e. phenytoin, phenobarbital, carbamazepine, rifampin, etc.) may also enhance clearance of SN-38, which may possibly decrease efficacy; therefore, concomitant administration of these drugs should be avoided; because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference for a list of drugs to avoid or minimize use of; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product

  • Uncontrolled intercurrent illness including, but not limited to, severe active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements; patients with chronic viral hepatitis may participate in this clinical trial if they are clinically stable with acceptable liver function

  • Pregnant women are excluded from this study because M6620 (VX-970, berzosertib) as a DNA-damage response (DDR) inhibitor may have the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with M6620 (VX-970, berzosertib), breastfeeding should be discontinued if the mother is treated with M6620 (VX-970, berzosertib); these potential risks may also apply to other agents used in this study

  • Human immunodeficiency virus (HIV)-positive patients with well-controlled disease, as determined by CD4 count and viral load, who are on antiretroviral therapy that does not contain a strong inducer or inhibitor of CYP3A4 (e.g. regimens containing ritonavir, cobicistat, efavirenz or etravirine) are allowed on trial; HIV-positive patients on combination antiretroviral therapy with strong inducers or inhibitors of CYP3A4 are ineligible because of the potential for pharmacokinetic interactions with M6620 (VX-970, berzosertib); patients with poorly controlled HIV are not eligible due to the increased risk of lethal infections when treated with marrow-suppressive therapy

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Treatment (irinotecan, M6620)

Patients receive irinotecan hydrochloride IV over 90 minutes and M6620 IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy and collection of blood samples throughout the study and undergo CT at screening, throughout the study, and during follow up.

Undergo CT

Andere Namen:
  • CT
  • KATZE
  • Computertomographie
  • Computergestützte axiale Tomographie
  • CT-Scan
  • Tomographie
  • Computerisierte Axialtomographie (Verfahren)
  • Computertomographie (CT)-Scan
  • Diagnosekatze Scan
  • Diagnose -Katzen -Scan -Service -Typ

Given IV

Andere Namen:
  • Campto
  • Camptosar
  • U-101440E
  • CPT-11
  • Camptothecin 11
  • Camptothecin-11
  • CPT 11
  • Irinomedac
  • Irinotecan-Hydrochlorid-Trihydrat
  • Irinotecan-Monohydrochlorid-Trihydrat
  • CPT11
  • U 101440E
  • U101440E

Given IV

Andere Namen:
  • 2-Pyrazinamin, 3-(3-(4-((Methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-
  • M6620
  • VX970
  • VX-970

Undergo biopsy

Andere Namen:
  • Biopsieprobe

Correlative studies

Andere Namen:
  • Biologische Probensammlung
  • Bioprobe gesammelt
  • Probenentnahme
  • Beispielsammlung

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Maximum tolerated dose (MTD)
Zeitfenster: Up to 28 days

Will be defined as the highest dose level at which =< 20% patients experience dose limiting toxicity. A logistic regression model will be used to determine the MTD using all patients.

Up to 28 days
Recommended phase 2 dose (RP2D) of ATR kinase inhibitor M6620 (VX-970, berzosertib) and irinotecan hydrochloride
Zeitfenster: Up to 28 days

The RP2D will be determined based on MTD and the feasibility of the administration.

Up to 28 days

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of adverse events of M6620 (VX-970, berzosertib) and irinotecan hydrochloride
Zeitfenster: Up to 6 months after completion of study treatment

Will be assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. A toxicity will be considered to be an adverse event that is possibly, probably or definitely related to treatment. The maximum grade of toxicity for each category of interest will be recorded for each patient, and the summary results will be tabulated by category, grade, and dose level. Serious (>= grade 3) toxicities will be described on a patient-by-patient basis and will include any relevant baseline data.

Up to 6 months after completion of study treatment
Overall response rate
Zeitfenster: Up to 6 months after completion of study treatment

Will be evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1. Tabulated by disease diagnosis and by dose level. Will also report the 95% confidence limits on the response rates. Will also report the response rate and confidence limits at that dose level separately.

Up to 6 months after completion of study treatment
Incidence of stable disease
Zeitfenster: Up to 6 months after completion of study treatment

Tabulated by disease diagnosis and by dose level. Will also report the response rate and confidence limits at that dose level separately.

Up to 6 months after completion of study treatment
Progression-free survival
Zeitfenster: Duration of time from start of treatment to time of progression or death, whichever occurs first, assessed up 6 months after completion of study treatment

Estimated using the Kaplan-Meier method and the corresponding 95% confidence interval will be provided.

Duration of time from start of treatment to time of progression or death, whichever occurs first, assessed up 6 months after completion of study treatment
Pharmacokinetic parameters of M6620 (VX-970, berzosertib) in combination with irinotecan hydrochloride
Zeitfenster: Days -14 through -11, 1, 2, and 15 through 18 of cycle 1 (each cycle = 28 days)

Within-subject comparison of day 15 and day -14 irinotecan hydrochloride and SN38 area under the curve (AUC) and half-life (t1/2) will be performed. Maximum concentration (Cmax), AUC, t1/2, clearance (CL), and volume in steady state (Vss) of VX-970 with single-agent historical data at comparable doses will be compared. Induction of gamma H2AX as a marker of ATR-dependent replication stress in peripheral blood mononuclear cells (PBMCs) and tumor will be characterized.

Days -14 through -11, 1, 2, and 15 through 18 of cycle 1 (each cycle = 28 days)
Pharmacodynamic parameters of M6620 (VX-970, berzosertib) in combination with irinotecan hydrochloride
Zeitfenster: Up to day 15 of cycle 1 (each cycle = 28 days)

Within-subject comparison of day 15 and day -14 irinotecan hydrochloride and SN38 AUC and t1/2 will be performed. Cmax, AUC, t1/2, CL, and Vss of VX-970 with single-agent historical data at comparable doses will be compared. Induction of gamma H2AX as a marker of ATR-dependent replication stress in PBMCs and tumor will be characterized.

Up to day 15 of cycle 1 (each cycle = 28 days)

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in biomarker levels
Zeitfenster: Baseline to up 6 months after completion of study treatment

Paired t tests will be used to compare biomarker levels before and after treatment. The Benjamini and Hochberg's procedure will be used to control the false discovery rate at 30%. A descriptive analysis of patient tumor genotype and response to therapy will be performed.

Baseline to up 6 months after completion of study treatment

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Liza C Villaruz, University of Pittsburgh Cancer Institute LAO

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

22. Juli 2016

Primärer Abschluss (Tatsächlich)

7. März 2023

Studienabschluss (Geschätzt)

6. März 2027

Studienanmeldedaten

Zuerst eingereicht

3. November 2015

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

3. November 2015

Zuerst gepostet (Geschätzt)

4. November 2015

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

12. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. November 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • NCI-2015-01915
  • UM1CA186689 (US NIH Stipendium/Vertrag)
  • UM1CA186704 (US NIH Stipendium/Vertrag)
  • UM1CA186690 (US NIH Stipendium/Vertrag)
  • UM1CA186717 (US NIH Stipendium/Vertrag)
  • NCI-2015-01915 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
  • HCC 15-164
  • UPCI 15-164
  • HCC#15-164
  • 9938 (Andere Kennung: CTEP)
  • 9938 (Andere Kennung: UPMC Hillman Cancer Center LAO)

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .